Table 3. Characteristics of AML patient... | American Society of Hematology

Table 3.

Characteristics of AML patient samples

Patient no.	WBC count, × 10⁹/L	FAB group	Karyotype	CD33, % of MNCs	CD34⁺CD38^-, %	CD33, % of CD34⁺CD38^-
1	151	1	Normal	76	0.24	19
2	40	2	Normal	68	0.37	26
3^*	22	2	+11, +13	96	13.5	100
4^*	66	2	t(8;21)	98	61	100
5	73	2	Normal	94	0.68	76
6	2.5	4	Normal	43	0.04	26
7	71	4	+3, +10	88	10	100
8	115	5	Normal	87	0.04	23
9†	12	NA	t(11;19)	58	0.47	95
10†	19	NA	Complex	79	31	96
11	2.2	4	Normal	96	7.8	83
12	77	4	Inv16	87	10.8	96
13	33	5	Normal	47	0.15	14

Patient no.	WBC count, × 10⁹/L	FAB group	Karyotype	CD33, % of MNCs	CD34⁺CD38^-, %	CD33, % of CD34⁺CD38^-
1	151	1	Normal	76	0.24	19
2	40	2	Normal	68	0.37	26
3^*	22	2	+11, +13	96	13.5	100
4^*	66	2	t(8;21)	98	61	100
5	73	2	Normal	94	0.68	76
6	2.5	4	Normal	43	0.04	26
7	71	4	+3, +10	88	10	100
8	115	5	Normal	87	0.04	23
9†	12	NA	t(11;19)	58	0.47	95
10†	19	NA	Complex	79	31	96
11	2.2	4	Normal	96	7.8	83
12	77	4	Inv16	87	10.8	96
13	33	5	Normal	47	0.15	14

WBC indicates white blood cell; FAB, French-American-British classification; NA, not applicable.

Samples taken at relapse

Therapy-related AML